Close Menu

NEW YORK – InterVenn Biosciences announced Monday it has raised $34 million in a Series B financing round to commercialize its ovarian cancer diagnostic.

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Don't have a 360Dx or GenomeWeb account?
Register for Free.